Optimizing Clinical Outcomes: A Nomogram for Predicting Gastric Cancer Survival in Elderly Patients Following Gastrectomy
Main Article Content
Abstract
Background: Owing to the aging global population, the prevalence of gastric cancer (GC) in the elderly is on the increase. The study aimed to investigate risk variables correlated with cancer-specific survival (CSS) and to construct and validate a nomogram to calculate the probability of CSS after gastrectomy in elderly patients with non-metastatic GC. Methods: Overall, 5462 postgastrectomy patients with geriatric non-metastatic GC who were diagnosed between 2006 and 2015, and 1078 patients diagnosed between 2004 and 2005 from the Surveillance, Epidemiology, and End Results (SEER) database were incorporated in this study. We randomly selected 3846 patients from the 5462 patients to constitute the training cohort to construct the nomogram, and the other 1616 patients were used for internal validation. Additionally, the other 1078 patients were used for external validation. CSS predictors were screened using univariate Cox proportional hazards regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis, Random Survival Forest (RSF), and multivariate Cox proportional hazards regression analysis. A model for predicting CSS was developed using Cox proportional hazards regression analysis, and both static and dynamic web-based nomograms were provided. Results: A total of 10 variables, including gender, age, race, tumor size, primary site, grade, positive lymph nodes (PLNs), examined lymph nodes (ELNs), T stage, and months from diagnosis to treatment (MFDTT), were incorporated in the development of the nomogram. The areas under the curve (AUCs) for the training cohort at 3, 5, and 10 years were 0.780 (95% CI, 0.765–0.795), 0.792 (95% CI, 0.778– 0.807), and 0.803 (95% CI, 0.781–0.826). Following internal validation, these values were 0.809 (95% CI, 0.789–0.830), 0.822 (95% CI, 0.801–0.843), and 0.824 (95% CI, 0.793–0.854). The model-predicted CSS converges with the actual CSS according to the calibration curves. The nomogram showed higher clinical benefit than the TNM staging system, according to the decision curve analysis (DCA) for all three cohorts. The nomogram score was utilized as a basis for grouping high- and low-risk patients, and significant statistical differences (p<0.0001) were demonstrated between the two groups in the Kaplan–Meier (K-M) curves. Conclusions: Our novel nomogram can conveniently and accurately predict CSS in elderly patients with non-metastatic GC after gastrectomy, which can assist clinicians in adopting individualized treatment strategies to improve the prognosis of elderly patients with GC.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
References
F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J Clin, vol. 68, no. 6, pp. 394-424, 2018, doi:10.3322/caac.21492.
J. Machlowska, J. Baj, M. Sitarz, R. Maciejewski, and R. Sitarz, “Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies,” Int J Mol Sci, vol. 21, no. 11, p. 4012, 2020, doi:10.3390/ijms21114012.
C. Allemani, H. K. Weir, H. Carreira, et al., “Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2),” Lancet, vol. 385, no. 9972, pp. 977-1010, 2015, doi:10.1016/S0140-6736(14)62038-9.
“Frailty in Older People,” Lancet, vol. 381, no. 9868, pp. 752-762, 2013, doi:10.1016/S0140-6736(12)62167-9.
T. Matsunaga, R. Ishiguro, W. Miyauchi, et al., “Appraisal of long-time outcomes after curative surgery in elderly patients with gastric cancer: a propensity score matching analysis,” BMC Surg, vol. 21, p. 33, 2021, doi:10.1186/s12893-021-01046-0.
H. Yazici, A. C. Esmer, A. Eren Kayaci, and S. C. Yegen, “Gastrıc cancer surgery in elderly patients: promising results from a mid-western population,” BMC Geriatr, vol. 23, no. 1, p. 529, 2023, doi:10.1186/s12877-023-04206-4.
Y. Choi, N. Kim, K. W. Kim, et al., “Gastric cancer in older patients: a retrospective study and literature review,” Ann Geriatr Med Res, vol. 26, no. 1, pp. 33-41, 2022, doi:10.4235/agmr.21.0144.
J. A. Ajani, T. A. D’Amico, D. J. Bentrem, et al., “Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology,” J Natl Compr Canc Netw, vol. 20, no. 2, pp. 167-192, 2022, doi:10.6004/jnccn.2022.0008.
J. Lu, Z. F. Zheng, J. W. Xie, et al., “Is the 8th Edition of the AJCC TNM Staging System Sufficiently Reasonable for All Patients with Noncardia Gastric Cancer? A 12,549-Patient International Database Study,” Ann Surg Oncol, vol. 25, no. 7, pp. 2002-2011, 2018, doi:10.1245/s10434-018-6447-0.
X. Y. Zhang and P. Y. Zhang, “Gastric cancer: somatic genetics as a guide to therapy,” J Med Genet., vol. 54, no. 5, pp. 305-312, 2017, doi:10.1136/jmedgenet-2016-104171.
I. Akushevich, J. Kravchenko, A. P. Yashkin, et al., “Time trends in the prevalence of cancer and non-cancer diseases among older U.S. adults: Medicare-based analysis,” Exp Gerontol., vol. 110, pp. 267-276, 2018, doi:10.1016/j.exger.2018.06.017.
J. A. Ajani, T. A. D’Amico, D. J. Bentrem, et al., “Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology,” J Natl Compr Canc Netw, vol. 20, no. 2, pp. 167-192, 2022, doi:10.6004/jnccn.2022.0008.
Z. Wang, J. Liu, Y. Luo, et al., “Establishment and verification of a nomogram for predicting the risk of lymph node metastasis in early gastric cancer,” Rev Esp Enferm Dig, vol. 113, no. 6, pp. 411-417, 2021, doi:10.17235/reed.2020.7102/2020.
G. Nie, H. Zhang, J. Yan, D. Xie, H. Zhang, and X. Li, “Construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma,” Front Oncol, vol. 13, p. 1114847, 2023, doi:10.3389/fonc.2023.1114847.
J. Schendel, E. Jost, M. Mah, et al., “Gastric cancer management in elderly patients: a population-based study of treatment patterns and outcomes in gastric cancer patients ≥75 years from Alberta, Canada,” Am J Surg, vol. 221, no. 4, pp. 839-843, 2021, doi:10.1016/j.amjsurg.2020.03.006.
S. D. Nelen, R. H. A. Verhoeven, V. E. P. P. Lemmens, J. H. W. de Wilt, and K. Bosscha, “Increasing survival gap between young and elderly gastric cancer patients,” Gastric Cancer, vol. 20, no. 6, pp. 919-928, 2017, doi:10.1007/s10120-017-0708-7.
Y. Chen, Y. Jia, Z. Peng, and G. Wang, “The prognostic role of tumor size in stage T1 gastric cancer,” World J Surg Oncol, vol. 20, no. 1, p. 135, 2022, doi:10.1186/s12957-022-02596-0.
G. M. Mranda, Y. Xue, X. G. Zhou, et al., “Revisiting the 8th AJCC system for gastric cancer: A review on validations, nomograms, lymph nodes impact, and proposed modifications,” Ann Med Surg, vol. 75, 2022, doi:10.1016/j.amsu.2022.103411.
M. Sierzega, L. Bobrzynski, P. Kolodziejczyk, et al., “Nomogram-Based Prognostic Evaluation of Gastric Cancer Patients with Low Counts of Examined Lymph Nodes Outperforms the Predictive Ability of the 7th and 8th Editions of the American Joint Committee on Cancer Staging System,” J Gastrointest Surg, vol. 27, no. 1, pp. 7-16, 2023, doi:10.1007/s11605-022-05334-9.
T. Tatara, S. Suzuki, S. Kanaji, et al., “Lymphopenia predicts poor prognosis in older gastric cancer patients after curative gastrectomy,” Geriatr Gerontol Int, vol. 19, no. 12, pp. 1215-1219, 2019, doi:10.1111/ggi.13794.
M. Roberto, A. Botticelli, L. Strigari, et al., “Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival,” Med Oncol, vol. 35, no. 7, p. 111, 2018, doi:10.1007/s12032-018-1166-8.
C. Díaz Del Arco, L. Ortega Medina, L. Estrada Muñoz, S. García Gómez de Las Heras, and M. J. Fernández Aceñero, “Pathologic lymph node staging of gastric cancer,” Am J Clin Pathol, vol. 156, no. 5, pp. 749-765, 2021, doi:10.1093/ajcp/aqab031.
H. Li, D. Lin, Z. Yu, et al., “A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer,” Front Immunol, vol. 13, p. 947802, 2022, doi:10.3389/fimmu.2022.947802.
L. Zhao, W. Han, X. Yang, et al., “Exceeding 30 ELNs is strongly recommended for pT3-4N0 patients with gastric cancer: A multicenter study of survival, recurrence, and prediction model,” Cancer Sci, vol. 112, no. 8, pp. 3266-3277, 2021, doi:10.1111/cas.15003.
J. Back, V. Sallinen, A. Kokkola, and P. Puolakkainen, “Surgical and oncological outcomes of D1 versus D2 gastrectomy among elderly patients treated for gastric cancer,” Scand J Surg, vol. 111, no. 2, p. 14574969221096193, 2022, doi:10.1177/14574969221096193.
F. Petrelli, M. Ghidini, S. Barni, et al., “Prognostic role of primary tumor location in non-metastatic gastric cancer: a systematic review and meta-analysis of 50 studies,” Ann Surg Oncol, vol. 24, no. 9, pp. 2655-2668, 2017, doi:10.1245/s10434-017-5832-4.
S. Zhang, L. Zheng, Y. Zhang, et al., “A web-based prediction model for long-term cancer-specific survival of middle-aged patients with early-stage gastric cancer: a multi-institutional retrospective study,” J Cancer Res Clin Oncol., published online September 15, 2023, doi:10.1007/s00432-023-05405-7.
H. Lu, Y. Sun, Z. Zhu, H. Xu, R. Huang, and B. Huang, “Differentiated/undifferentiated mixed type is a prognostic factor for T2/T3 gastric cancer patients,” Expert Rev Gastroenterol Hepatol, vol. 15, no. 11, pp. 1329-1336, 2021, doi:10.1080/17474124.2021.1973430.
S. H. Park, D. H. Lim, T. S. Sohn, et al., “A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆,” Ann Oncol, vol. 32, no. 3, pp. 368-374, 2021, doi:10.1016/j.annonc.2020.11.017.
N. Zhang, Q. Fei, J. Gu, L. Yin, and X. He, “Progress of preoperative and postoperative radiotherapy in gastric cancer,” World J Surg Oncol, vol. 16, no. 1, p. 187, 2018, doi:10.1186/s12957-018-1490-7.
Y. W. Zhang, Y. L. Zhang, H. Pan, et al., “Chemotherapy for patients with gastric cancer after complete resection: a network meta-analysis,” World J Gastroenterol, vol. 20, no. 2, pp. 584-592, 2014, doi:10.3748/wjg.v20.i2.584.
D. H. Ilson, “Advances in the treatment of gastric cancer,” Curr Opin Gastroenterol, vol. 36, no. 6, pp. 525-529, 2020, doi:10.1097/MOG.0000000000000679.
W. You, Z. Cai, N. Sheng, et al., “Construction and validation of convenient clinicopathologic signatures for predicting the prognosis of stage I-III gastric cancer,” Front Oncol, vol. 12, p. 848783, 2022, doi:10.3389/fonc.2022.848783.
C. Li, M. Wang, X. Cheng, Y. Jiang, and H. Xiao, “Nerve invasion as an independent predictor of poor prognosis in gastric cancer after curative resection,” Med (Baltim), vol. 101, no. 33, p. e30084, 2022, doi:10.1097/MD.0000000000030084.
K. Chang, B. Song, I. G. Do, et al., “Venous invasion and perineural invasion as upstaging and poor prognostic factors in N0 gastric cancers,” Anticancer Res, vol. 41, no. 11, pp. 5803-5810, 2021, doi:10.21873/anticanres.15397.
“Association of clinical parameters and prognosis with the pretreatment systemic immune-inflammation index (SII) in patients with gastric cancer,” J Coll Physicians Surg Pak., published online January 1, 2021, pp. 83-88, doi:10.29271/jcpsp.2021.01.83.
M. Yildirim and B. Koca, “Lymphocyte C-reactive protein ratio: A new biomarker to predict early complications after gastrointestinal oncologic surgery,” CBM, vol. 31, no. 4, pp. 409-417, 2021, doi:10.3233/CBM-210251.
X. Wang, M. Mao, S. Zhu, et al., “A novel nomogram integrated with inflammation-based factors to predict the prognosis of gastric cancer patients,” Adv Ther, vol. 37, no. 6, pp. 2902-2915, 2020, doi:10.1007/s12325-020-01356-4.
A. Rojas, P. Araya, I. Gonzalez, and E. Morales, “Gastric tumor microenvironment,” Adv Exp Med Biol, vol. 1226, pp. 23-35, 2020, doi:10.1007/978-3-030-36214-0_2.
D. Zeng, M. Li, R. Zhou, et al., “Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures,” Cancer Immunol Res, vol. 7, no. 5, pp. 737-750, 2019, doi:10.1158/2326-6066.CIR-18-0436.
F. Marliot, F. Pagès, and J. Galon, “Usefulness and robustness of Immunoscore for personalized management of cancer patients,” Oncoimmunology, vol. 9, no. 1, p. 1832324, 2020, doi:10.1080/2162402X.2020.1832324.